Provectus Pharmaceutical Inc (OTC:PVCT) has sank into price hesitations lately. Over the past week, the stock has been 
constantly getting hot and cold and yesterday its price decreased again. Unlike the price fall, traded volume of PVCT rose up. But what is the reason for the changeable stock movement?
The latest news by PVCT came up a couple of days ago, regarding some changes in its Board of Directors and Advisory Board. However, apart from these announcements, no other information on the company’s projects was released. So, presently no one is familiar with its activities.
The only data available points out high trading activity with PVCT shares of common stock throughout this month. According to the forms filed with the SEC, some of the company’s directors as well as its President, have been actively buying PVCT shares lately with no explanation. Is it an indication that something is about to happen with Provectus is just a matter of time to be seen.[BANNER]
Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. As of March 31, this year the company’s 10-Q report states:
* $12 million current assets;
* $718k current liabilities;
* $91 million accumulated deficit;
* $5 million net loss.
At first sight, the balance doesn’t look so bad, though investors should look again. The results of Phase 3 clinical trials are still expected and these are yet to be commenced. However, having in mind the huge accumulated deficit and the fact that the trials need additional funding is worth to be well-considered.
